Issued: London, UK
\r\nFor media and investors only
","shortDescription":"Decision on EU marketing authorisation expected for momelotinib by early 2024.","image":null,"downloadLink":{"text":"Download (PDF - 206.5KB)","href":"/media/d2vgpweh/mmb-chmp-opinion-press-release.pdf","title":"Opens in a new window","target":"_blank"},"tags":[]},"components":[{"type":"rich-text","text":"GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of momelotinib for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
\nThe CHMP opinion is one of the final steps prior to a marketing authorisation decision by the European Commission. If approved, momelotinib would be the only medicine in the European Union (EU) specifically indicated for both newly diagnosed and previously treated myelofibrosis patients with moderate to severe anaemia that addresses splenomegaly and symptoms.
\nNina Mojas, Senior Vice President, Oncology Global Product Strategy, GSK, said: “Momelotinib has a differentiated mechanism of action that may address the significant medical needs of myelofibrosis patients, especially those with moderate to severe anaemia. The vast majority of myelofibrosis patients will develop anaemia, causing them to require transfusions and leading a notable proportion to discontinue treatment. This positive CHMP opinion is a significant step in bringing momelotinib to patients in the EU with this difficult-to-treat blood cancer.”
\nThe positive CHMP opinion is supported by data from the pivotal MOMENTUM study and a subpopulation of adult patients with moderate to severe anaemia (haemoglobin <10 g/dL) from the SIMPLIFY-1 phase III trial.1,2 MOMENTUM was designed to evaluate the safety and efficacy of momelotinib versus danazol for the treatment and reduction of key manifestations of myelofibrosis in an anaemic, symptomatic, JAK inhibitor-experienced population. SIMPLIFY-1 was designed to evaluate the efficacy and safety of momelotinib versus ruxolitinib in myelofibrosis patients who had not received a prior JAK-inhibitor therapy.
\nIn these clinical trials, the most common adverse reactions were diarrhoea, thrombocytopaenia, nausea, headache, dizziness, fatigue, asthenia, abdominal pain and cough.1,2
\nIf approved in the EU, momelotinib will be available under the proposed trade name Omjjara. This opinion follows the September 2023 approval of momelotinib under the brand name Ojjaara by the US Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia. Momelotinib is not approved in any other market.
\nMomelotinib has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1).1,3,4,5 Inhibition of JAK1 and JAK2 may improve constitutional symptoms and splenomegaly.1,3,5 Additionally, inhibition of ACVR1 leads to a decrease in circulating hepcidin levels, potentially contributing to anaemia benefit.1,3,4,5
\nMyelofibrosis is a rare blood cancer that disrupts the body’s normal production of blood cells because of dysregulated JAK-signal transducer and activator of transcription protein signalling. The clinical hallmarks of myelofibrosis are splenomegaly (enlarged spleen), progressive anaemia and debilitating constitutional symptoms, such as fatigue, night sweats and bone pain, attributable to ineffective haematopoiesis and excessive production of proinflammatory cytokines.6
\nAbout 40% of patients have moderate to severe anaemia at the time of diagnosis and nearly all patients are estimated to develop anaemia over the course of the disease.7,8,9,10 Myelofibrosis patients with anaemia require additional supportive care, including transfusions, and more than 30% will discontinue treatment due to anaemia.11 Patients who are transfusion dependent have a poor prognosis and shortened survival.3, 12,13,14,15,16,17,18,19
\nMOMENTUM was a phase III, global, multicentre, randomised, double-blind study investigating momelotinib versus danazol in patients with myelofibrosis who were symptomatic and anaemic and had been previously treated with an approved JAK inhibitor. The trial was designed to evaluate the safety and efficacy of momelotinib for treating and reducing key hallmarks of the disease: symptoms, blood transfusions (due to anaemia) and splenomegaly. The MOMENTUM trial met all its primary and key secondary endpoints, demonstrating statistically significant response with respect to constitutional symptoms, splenic response and transfusion independence, in patients treated with momelotinib versus danazol.20 Results from the 24-week randomised treatment period were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and subsequently published in The Lancet,21,22 with 48-week data presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2022 and subsequently published in The Lancet.23,24
\nSIMPLIFY-1 was a multicentre, randomised, double-blind, phase III study that compared the safety and efficacy of momelotinib to ruxolitinib in patients with myelofibrosis who had not received prior treatment with a JAK inhibitor. Safety and efficacy results for SIMPLIFY-1 were based upon a subset of patients with anaemia at baseline. The efficacy of momelotinib in the treatment of patients with myelofibrosis in SIMPLIFY-1 was based on spleen volume response (reduction of spleen volume by 35% or greater).
\nGSK is committed to maximising patient survival through transformational medicines, with a current focus on breakthroughs in immuno-oncology and tumour-cell targeting therapies, and development in haematologic malignancies, gynaecologic cancers and other solid tumours.
\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
\nGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, and Q3 Results for 2023.
\nSwitch to dark mode to head towards a more sustainable world together. More info
"},"globalSiteLink":null,"locationSelector":{"text":"Change location","href":"/en-gb/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":true,"title":"Behind the Science magazine","url":"/en-gb/behind-the-science-magazine/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-gb/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-gb/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"Outstanding people","url":"/en-gb/company/outstanding-people/","nodes":[{"title":"Great place to work","url":"/en-gb/company/outstanding-people/great-place-to-work/","nodes":[],"isActive":false},{"title":"Meet our veterans","url":"/en-gb/company/outstanding-people/meet-our-veterans/","nodes":[],"isActive":false},{"title":"Working together","url":"/en-gb/company/outstanding-people/working-together/","nodes":[],"isActive":false},{"title":"My GSK story","url":"/en-gb/company/outstanding-people/my-gsk-story/","nodes":[],"isActive":false},{"title":"Innovating together","url":"/en-gb/company/outstanding-people/innovating-together/","nodes":[],"isActive":false}],"isActive":false},{"title":"GSK at a glance","url":"/en-gb/company/gsk-at-a-glance/","nodes":[],"isActive":false},{"title":"History and heritage","url":"/en-gb/company/history-and-heritage/","nodes":[],"isActive":false},{"title":"Board of Directors and Executive Committee","url":"/en-gb/company/board-of-directors-and-leadership-team/","nodes":[],"isActive":false},{"title":"Board information","url":"/en-gb/company/board-information/","nodes":[],"isActive":false},{"title":"Governance","url":"/en-gb/company/governance/","nodes":[{"title":"Committees","url":"/en-gb/company/governance/committees/","nodes":[],"isActive":false},{"title":"Shareholders","url":"/en-gb/company/governance/shareholders/","nodes":[],"isActive":false},{"title":"Sarbanes-Oxley Act 2002","url":"/en-gb/company/governance/sarbanes-oxley-act-2002/","nodes":[],"isActive":false},{"title":"Compliance","url":"/en-gb/company/governance/compliance/","nodes":[],"isActive":false}],"isActive":false},{"title":"Policy positions","url":"/en-gb/company/policy-positions/","nodes":[],"isActive":false},{"title":"Codes, standards and reports","url":"/en-gb/company/codes-standards-and-reports/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Our purpose, strategy and culture","image":{"src":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=100&v=1dba2ec0bc1e680","alt":"GSK Tech Human Image","darkModeSrc":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=50&v=1dba2ec0bc1e680"},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/purpose-strategy-and-culture/","openInNewWindowText":null}},{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0"},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/outstanding-people/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-gb/innovation/","nodes":[{"title":"Our leading scientists","url":"/en-gb/innovation/our-leading-scientists/","nodes":[{"title":"Dr Tony Wood","url":"/en-gb/innovation/our-leading-scientists/tony-wood/","nodes":[],"isActive":false},{"title":"Dr Sabine Luik","url":"/en-gb/innovation/our-leading-scientists/sabine-luik/","nodes":[],"isActive":false},{"title":"Dr Hesham Ahmed Abdullah","url":"/en-gb/innovation/our-leading-scientists/hesham-abdullah/","nodes":[],"isActive":false},{"title":"Dr Kaivan Khavandi","url":"/en-gb/innovation/our-leading-scientists/kaivan-khavandi/","nodes":[],"isActive":false},{"title":"Dr Christopher Austin","url":"/en-gb/innovation/our-leading-scientists/dr-christopher-austin/","nodes":[],"isActive":false}],"isActive":false},{"title":"Research and development approach","url":"/en-gb/innovation/research-and-development-approach/","nodes":[],"isActive":false},{"title":"Pipeline","url":"/en-gb/innovation/pipeline/","nodes":[],"isActive":false},{"title":"Therapeutic areas","url":"/en-gb/innovation/therapeutic-areas/","nodes":[{"title":"Respiratory, immunology and inflammation","url":"/en-gb/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"Oncology","url":"/en-gb/innovation/therapeutic-areas/oncology/","nodes":[],"isActive":false},{"title":"HIV","url":"/en-gb/innovation/therapeutic-areas/hiv/","nodes":[],"isActive":false},{"title":"Infectious diseases","url":"/en-gb/innovation/therapeutic-areas/infectious-diseases/","nodes":[],"isActive":false}],"isActive":false},{"title":"Tech","url":"/en-gb/innovation/technologies/","nodes":[],"isActive":false},{"title":"Clinical trials at GSK","url":"/en-gb/innovation/trials/","nodes":[{"title":"Provision of unapproved medicines for unmet medical needs","url":"/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/","nodes":[],"isActive":false},{"title":"Data transparency","url":"/en-gb/innovation/trials/data-transparency/","nodes":[],"isActive":false},{"title":"Representative clinical studies","url":"/en-gb/innovation/trials/representative-clinical-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"Partnering with GSK","url":"/en-gb/innovation/partnerships/","nodes":[{"title":"Supported studies","url":"/en-gb/innovation/partnerships/supported-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"R&D locations","url":"/en-gb/innovation/rd-locations/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}},{"text":"Our leading scientists","image":{"src":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=100&v=1dc651e856734f0","alt":"Tony Wood","darkModeSrc":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=50&v=1dc651e856734f0"},"link":{"text":"Featured section","href":"/en-gb/innovation/our-leading-scientists/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-gb/products/","nodes":[{"title":"Product areas","url":"/en-gb/products/our-product-areas/","nodes":[],"isActive":false},{"title":"Products A-Z","url":"/en-gb/products/products-a-z/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Innovation","image":{"src":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe22d650","alt":"Lab technician leaning against wall","darkModeSrc":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe22d650"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/","openInNewWindowText":null}},{"text":"GSKPro for healthcare professionals ","image":{"src":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe35c210","alt":"Two scientists on orange background","darkModeSrc":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe35c210"},"link":{"text":"FEATURED WEBSITE","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-gb/responsibility/","nodes":[{"title":"Access","url":"/en-gb/responsibility/access/","nodes":[],"isActive":false},{"title":"Global health and health security","url":"/en-gb/responsibility/global-health-and-health-security/","nodes":[{"title":"Global health","url":"/en-gb/responsibility/global-health-and-health-security/global-health/","nodes":[],"isActive":false},{"title":"Health security","url":"/en-gb/responsibility/global-health-and-health-security/health-security/","nodes":[],"isActive":false},{"title":"Using our science for global health","url":"/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/","nodes":[],"isActive":false},{"title":"Improving access to healthcare","url":"/en-gb/responsibility/global-health-and-health-security/improving-access-to-healthcare/","nodes":[],"isActive":false},{"title":"Africa Open Lab","url":"/en-gb/responsibility/global-health-and-health-security/africa-open-lab/","nodes":[],"isActive":false}],"isActive":false},{"title":"Environment","url":"/en-gb/responsibility/environment/","nodes":[{"title":"Climate","url":"/en-gb/responsibility/environment/climate/","nodes":[],"isActive":false},{"title":"Freshwater","url":"/en-gb/responsibility/environment/freshwater/","nodes":[],"isActive":false},{"title":"Land","url":"/en-gb/responsibility/environment/land/","nodes":[],"isActive":false},{"title":"Oceans","url":"/en-gb/responsibility/environment/oceans/","nodes":[],"isActive":false},{"title":"Materials and waste","url":"/en-gb/responsibility/environment/materials-and-waste/","nodes":[],"isActive":false},{"title":"Health system sustainability","url":"/en-gb/responsibility/environment/health-system-sustainability/","nodes":[],"isActive":false}],"isActive":false},{"title":"Inclusion","url":"/en-gb/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-gb/responsibility/ethical-standards/","nodes":[{"title":"Working with third parties","url":"/en-gb/responsibility/ethical-standards/working-with-third-parties/","nodes":[],"isActive":false},{"title":"Public policy and patient advocacy","url":"/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","nodes":[],"isActive":false},{"title":"Human rights","url":"/en-gb/responsibility/ethical-standards/human-rights/","nodes":[],"isActive":false},{"title":"Use of animals","url":"/en-gb/responsibility/ethical-standards/use-of-animals/","nodes":[],"isActive":false},{"title":"Engaging with healthcare professionals","url":"/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false}],"isActive":false},{"title":"Product governance","url":"/en-gb/responsibility/product-governance/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-gb/responsibility/grants-and-donations/","nodes":[],"isActive":false},{"title":"Charitable investments ","url":"/en-gb/responsibility/charitable-investments/","nodes":[],"isActive":false},{"title":"Responsibility reports","url":"/en-gb/responsibility/responsibility-reports/","nodes":[{"title":"Reports archive","url":"/en-gb/responsibility/responsibility-reports/responsibility-reports-archive/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030"},"link":{"text":"FEATURED SECTION","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}},{"text":"Our policy positions","image":{"src":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe9b61b0","alt":"GSK orange texture","darkModeSrc":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe9b61b0"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/company/policy-positions/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Investors","url":"/en-gb/investors/","nodes":[{"title":"Why invest in GSK?","url":"/en-gb/investors/why-invest-in-gsk/","nodes":[],"isActive":false},{"title":"Quarterly results","url":"/en-gb/investors/quarterly-results/","nodes":[],"isActive":false},{"title":"Financial reports","url":"/en-gb/investors/financial-reports/","nodes":[{"title":"Annual Report 2025","url":"/en-gb/investors/financial-reports/annual-report-2025/","nodes":[],"isActive":false},{"title":"Corporate reports archive","url":"/en-gb/investors/financial-reports/corporate-reports-archive/","nodes":[],"isActive":false}],"isActive":false},{"title":"Responsible business","url":"/en-gb/investors/responsible-business/","nodes":[],"isActive":false},{"title":"Speeches and presentations","url":"/en-gb/investors/speeches-and-presentations/","nodes":[],"isActive":false},{"title":"Science publications","url":"/en-gb/investors/science-publications/","nodes":[],"isActive":false},{"title":"Events calendar","url":"/en-gb/investors/events-calendar/","nodes":[],"isActive":false},{"title":"Dividend and share price","url":"/en-gb/investors/dividend-and-share-price/","nodes":[{"title":"GSK share price","url":"/en-gb/investors/dividend-and-share-price/gsk-share-price/","nodes":[],"isActive":false},{"title":"Share price calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calendar","url":"/en-gb/investors/dividend-and-share-price/dividend-calendar/","nodes":[],"isActive":false}],"isActive":false},{"title":"Analyst consensus","url":"/en-gb/investors/analyst-consensus/","nodes":[],"isActive":false},{"title":"Stock exchange announcements","url":"/en-gb/investors/stock-exchange-announcements/","nodes":[{"title":"London (RNS)","url":"/en-gb/investors/stock-exchange-announcements/london-rns/","nodes":[],"isActive":false},{"title":"London (RNS) inside information","url":"/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/","nodes":[],"isActive":false},{"title":"New York (SEC)","url":"/en-gb/investors/stock-exchange-announcements/new-york-sec/","nodes":[],"isActive":false},{"title":"Sign up for announcements","url":"/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/","nodes":[],"isActive":false}],"isActive":false},{"title":"Shareholder information","url":"/en-gb/investors/shareholder-information/","nodes":[{"title":"Manage your shares","url":"/en-gb/investors/shareholder-information/manage-your-shares/","nodes":[],"isActive":false},{"title":"Annual General Meeting","url":"/en-gb/investors/shareholder-information/annual-general-meeting/","nodes":[],"isActive":false},{"title":"General Meeting","url":"/en-gb/investors/shareholder-information/general-meeting/","nodes":[],"isActive":false},{"title":"Annual Governance Meeting","url":"/en-gb/investors/shareholder-information/annual-governance-meeting/","nodes":[],"isActive":false},{"title":"Corporate sponsored nominee service","url":"/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/","nodes":[],"isActive":false},{"title":"Our ADR programme","url":"/en-gb/investors/shareholder-information/adr-programme/","nodes":[],"isActive":false},{"title":"Asset reunification - Georgeson ","url":"/en-gb/investors/shareholder-information/asset-reunification-georgeson/","nodes":[],"isActive":false},{"title":"Share scam alert","url":"/en-gb/investors/shareholder-information/share-scam-alert/","nodes":[],"isActive":false},{"title":"Privacy notice for ordinary shareholders","url":"/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/","nodes":[],"isActive":false},{"title":"FAQs","url":"/en-gb/investors/shareholder-information/shareholder-faqs/","nodes":[],"isActive":false}],"isActive":false},{"title":"Corporate actions","url":"/en-gb/investors/corporate-actions/","nodes":[{"title":"Consumer Healthcare Demerger","url":"/en-gb/investors/corporate-actions/consumer-healthcare-demerger/","nodes":[],"isActive":false},{"title":"Consumer Healthcare Joint Venture","url":"/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/","nodes":[],"isActive":false},{"title":"Agreement to acquire TESARO","url":"/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/","nodes":[],"isActive":false}],"isActive":false},{"title":"Debt investors","url":"/en-gb/investors/debt-investors/","nodes":[],"isActive":false},{"title":"Investor contacts","url":"/en-gb/investors/investor-contacts/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Press releases","image":{"src":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc6f12bb0","alt":"Lab machinery","darkModeSrc":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc6f12bb0"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/media/press-releases/","openInNewWindowText":null}},{"text":"Our pipeline","image":{"src":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc701f490","alt":"Case of vials","darkModeSrc":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc701f490"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/pipeline/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-gb/media/","nodes":[{"title":"Press releases","url":"/en-gb/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-gb/media/media-contacts/","nodes":[],"isActive":false},{"title":"Media library","url":"/en-gb/media/media-library/","nodes":[],"isActive":false},{"title":"Zantac litigation","url":"/en-gb/media/zantac-litigation/","nodes":[],"isActive":false},{"title":"GSK's position on Flovent","url":"/en-gb/media/gsks-position-on-flovent/","nodes":[],"isActive":false},{"title":"Our social media","url":"/en-gb/media/social-media/","nodes":[],"isActive":false},{"title":"Podcasts","url":"/en-gb/media/podcasts/","nodes":[],"isActive":false},{"title":"RSS feeds","url":"/en-gb/media/rss-feeds/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130"},"link":{"text":"Spotlight on","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-gb/careers/","nodes":[{"title":"Search jobs","url":"/en-gb/careers/search-jobs/","nodes":[],"isActive":false},{"title":"Featured careers","url":"/en-gb/careers/featured-careers/","nodes":[{"title":"A career in data","url":"/en-gb/careers/featured-careers/a-career-in-data/","nodes":[],"isActive":false}],"isActive":false},{"title":"Life at GSK","url":"/en-gb/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Experienced professionals","url":"/en-gb/careers/experienced-professionals/","nodes":[{"title":"Business operations","url":"/en-gb/careers/experienced-professionals/business-operations/","nodes":[],"isActive":false},{"title":"Engineering at GSK ","url":"/en-gb/careers/experienced-professionals/engineering/","nodes":[],"isActive":false},{"title":"Global supply chain","url":"/en-gb/careers/experienced-professionals/global-supply-chain/","nodes":[],"isActive":false},{"title":"Sales and marketing","url":"/en-gb/careers/experienced-professionals/sales-and-marketing/","nodes":[],"isActive":false},{"title":"Research and development","url":"/en-gb/careers/experienced-professionals/research-and-development/","nodes":[{"title":"Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS)","url":"/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/","nodes":[],"isActive":false},{"title":"Genomic sciences","url":"/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/","nodes":[],"isActive":false}],"isActive":false},{"title":"Technology","url":"/en-gb/careers/experienced-professionals/technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Early careers","url":"/en-gb/careers/early-careers/","nodes":[{"title":"Application process","url":"/en-gb/careers/early-careers/application-process/","nodes":[],"isActive":false},{"title":"Apprentice programmes","url":"/en-gb/careers/early-careers/apprentice-programmes/","nodes":[],"isActive":false},{"title":"Internships and placements","url":"/en-gb/careers/early-careers/internships-and-placements/","nodes":[],"isActive":false},{"title":"Graduate programme","url":"/en-gb/careers/early-careers/graduate-programme/","nodes":[{"title":"Business operations","url":"/en-gb/careers/early-careers/graduate-programme/business-operations/","nodes":[],"isActive":false},{"title":"Engineering","url":"/en-gb/careers/early-careers/graduate-programme/engineering/","nodes":[],"isActive":false},{"title":"Manufacturing & supply","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-supply/","nodes":[],"isActive":false},{"title":"Commercial ","url":"/en-gb/careers/early-careers/graduate-programme/commercial/","nodes":[],"isActive":false},{"title":"Research & development","url":"/en-gb/careers/early-careers/graduate-programme/research-development/","nodes":[],"isActive":false},{"title":"Digital & tech","url":"/en-gb/careers/early-careers/graduate-programme/digital-tech/","nodes":[],"isActive":false},{"title":"Manufacturing sciences & technology","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-sciences-technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Post graduate opportunities","url":"/en-gb/careers/early-careers/post-graduate-opportunities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/early-careers/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false},{"title":"Veterans","url":"/en-gb/careers/veterans/","nodes":[],"isActive":false},{"title":"Our global and regional hubs","url":"/en-gb/careers/our-global-and-regional-hubs/","nodes":[],"isActive":false},{"title":"How we hire","url":"/en-gb/careers/how-we-hire/","nodes":[{"title":"Fraudulent internet recruitment activities","url":"/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/how-we-hire/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0"},"link":{"text":"Spotlight on","href":"/en-gb/company/outstanding-people/","openInNewWindowText":null}},{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030"},"link":{"text":"Spotlight on","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}}]}],"skipToContent":"Skip to content","skipToSearch":"Skip to search","typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=1703","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-gb/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"This is our global website, intended for visitors seeking information on GSK's worldwide business. Our market sites can be reached by visiting our location selector.
\n\n
© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nRegistered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG
","modernSlaveryStatement":{"name":"Modern Slavery Act Statement 2025","url":"/media/5ladhmeu/modern-slavery-act-statement-2025.pdf","fileExtension":"PDF","fileSize":"187.7KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK on Linkedin","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"http://twitter.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK X page","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":null,"href":"https://bsky.app/profile/gsk.bsky.social/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"","customIcon":null,"showPopupMenu":false,"type":"Bluesky"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Facebook page","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK YouTube Channel","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"/en-gb/media/rss-feeds/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Visit GSK RSS feeds","customIcon":null,"showPopupMenu":false,"type":"Rss"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"Locations selector","href":"/en-gb/locations/","openInNewWindowText":null},{"text":"Social media directory","href":"/en-gb/media/social-media/","openInNewWindowText":null},{"text":"GSKPro for healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK study register","href":"https://www.gsk-studyregister.com/en/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Behind the Science magazine","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null},{"text":"Company","href":"/en-gb/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-gb/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-gb/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-gb/responsibility/","openInNewWindowText":null},{"text":"Investors","href":"/en-gb/investors/","openInNewWindowText":null},{"text":"Media","href":"/en-gb/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-gb/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},{"text":"Partnerships","href":"/en-gb/innovation/partnerships/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-gb/contact-us/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-gb/accessibility/","openInNewWindowText":null},{"text":"Digital sustainability","href":"/en-gb/digital-sustainability/","openInNewWindowText":null},{"text":"Terms of use","href":"/en-gb/terms-of-use/","openInNewWindowText":null},{"text":"Cookie policy","href":"/en-gb/cookie-policy/","openInNewWindowText":null},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-gb/privacy-notice/general","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-gb/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"Decision on EU marketing authorisation expected for momelotinib by early 2024.","og":[{"property":"og:title","content":"GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia"},{"property":"og:description","content":"Decision on EU marketing authorisation expected for momelotinib by early 2024."},{"property":"og:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530"},{"property":"og:url","content":"https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia"},{"name":"twitter:description","content":"Decision on EU marketing authorisation expected for momelotinib by early 2024."},{"name":"twitter:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530"},{"name":"twitter:url","content":"https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":false,"title":"","texts":"","continueText":"Continue","cancelText":"Cancel","exclusionUrls":[]},"settings":{"optionalStylesheetLink":null,"themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=100&v=1dbf4b05a4e6470","alt":"Gsk Logo","darkModeSrc":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=50&v=1dbf4b05a4e6470"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":null,"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"70ab0a79-1d92-4286-86d2-abdd71cc785c","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":{"title":"","text":"You are about to access GSK historic archived press release material retained as a corporate record. References to products or their uses may be out of date and not reflect current medical, safety or regulatory information. For clinical information, consult the approved national product label information (SmPC).
","continueText":"Continue","cancelText":"Cancel"},"protectedPage":false,"schema":{"jsonLdSchemas":["{\"@context\":\"https://schema.org\",\"@type\":\"NewsArticle\",\"description\":\"Decision on EU marketing authorisation expected for momelotinib by early 2024.\",\"mainEntityOfPage\":\"https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia/\",\"author\":{\"@type\":\"Organization\",\"name\":\"GSK\",\"url\":\"https://www.gsk.com/en-gb/\"},\"datePublished\":\"2023-11-13T17:23:12+00:00\",\"headline\":\"GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia\",\"keywords\":\"Research and development,Medicines,Corporate\",\"articleSection\":\"Press releases\"}"]}}